ACCREDITATION STATEMENT The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation. The Endocrine Society designates this enduring activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. STATEMENT OF INDEPENDENCE As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations DISCLAIMER The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society. LEARNING OBJECTIVES Upon completion of this educational activity, learners will be able to: Apply clinical guidelines for diagnosis of Cushing's syndrome Review the consequences of excess cortisol exposure Evaluate patient response to therapy for Cushing's syndrome Assess available therapies, including new medical options for Cushing's syndrome TARGET AUDIENCE This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows and any healthcare professional involved in the care of patients with Cushing's syndrome. DISCLOSURE POLICY The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable. The following faculty reported relevant financial relationships: Beverly M.K. Biller, MD, FACP: Consultant, Novartis Pharmaceuticals Corporation; Research grant support, Corcept Therapeutics, Novartis Pharmaceuticals Corporation. James W. Findling, MD: Consultant, Corcept Therapeutics, Novartis Pharmaceuticals Corporation. John Newell-Price, MA, PhD, FRCP: Consultant and Speaker, Novartis Pharmaceuticals Corporation; Research grant support, HRA Pharma, Novartis Pharmaceuticals Corporation. The following faculty reported no relevant financial relationships: Paul M. Stewart, MD, FRCP, FMedSci. The following SPC member who planned and reviewed content for this activity reported relevant financial relationships: Laurence Katznelson, MD: Consultant, Novartis Pharmaceuticals Corporation; Speaker, Ipsen, Novo Nordisk Inc. POLICY ON UNLABELED/OFF-LABEL USE The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events. PRIVACY AND CONFIDENTIALITY STATEMENT The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties. ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT This activity is supported by an educational grant from Corcept Therapeutics. METHOD OF PARTICIPATION This enduring material is presented in an online/computer-based format. System requirements include: For Windows, Firefox 1.5 or Internet Explorer 7.0 with Flash 8 or better installed. For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed. To receive a maximum of 2.0 AMA PRA Category 1 Credits™, participants should: Select a session and listen to the audio and/or view the slides. Complete the evaluation provided at the end of the session and click on "submit" to add the session to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions. Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions. Credits awarded correspond to the length of time for each session, which varies from 0.5 to 1.0 hours. The estimated time to complete this activity, including review of material, is 2.0 hours. Last Review Date: June 2011 Activity Release/Expiration Date: June 2011 through June 2012 For technical assistance or information, please contact Content Management Corporation at 972-910-6899 (Monday - Friday 9:00 AM to 5:00 PM EST) or multiviewMediaSupport@multiview.com. For questions about content or obtaining CME credit, please contact The Endocrine Society at education@endo-society.org.

I have read the CME guidelines outlined.